This article was originally published in Start Up
Executive SummaryCell therapy start-up Nucleotech LLC is developing an in vitro method for reprogramming mature cells, transdifferentiating them into other kinds of mature cells for autologous therapeutic use against diabetes, cancer, cardiac disease and a host of other indications.
You may also be interested in...
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)
We nominated 15 deals in three categories. You picked the winners.